Related references
Note: Only part of the references are listed.The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
Johann Foloppe et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Optimizing oncolytic virotherapy in cancer treatment
Kevin Harrington et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
Shruthi Naik et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours
C. C. Hwang et al.
VETERINARY AND COMPARATIVE ONCOLOGY (2018)
Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy
Teresa Cejalvo et al.
CANCER RESEARCH (2018)
Clinical, Pathological, and Ethical Considerations for the Conduct of Clinical Trials in Dogs with Naturally Occurring Cancer: A Comparative Approach to Accelerate Translational Drug Development
Daniel Regan et al.
ILAR JOURNAL (2018)
Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma
Amy L. MacNeill et al.
VIRUSES-BASEL (2018)
Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study)
Galina V. Ilyinskaya et al.
FRONTIERS IN VETERINARY SCIENCE (2018)
Genetically engineered vaccinia viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery
Dana Haddad
FRONTIERS IN ONCOLOGY (2017)
Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma
Loren K. Mell et al.
CLINICAL CANCER RESEARCH (2017)
Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers
Stephanie Downs-Canner et al.
MOLECULAR THERAPY (2016)
Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1
[Anonymous]
VETERINARY AND COMPARATIVE ONCOLOGY (2016)
Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma
Che-Hsuan Kung et al.
BMC CANCER (2015)
Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles
Karoliina P. M. Autio et al.
BMC VETERINARY RESEARCH (2015)
Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients
Timothy P. Cripe et al.
MOLECULAR THERAPY (2015)
First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity
Herbert J. Zeh et al.
MOLECULAR THERAPY (2015)
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
H. Ruth Ashbee et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
New viruses for cancer therapy: meeting clinical needs
Tanner S. Miest et al.
NATURE REVIEWS MICROBIOLOGY (2014)
Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles
Karoliina Autio et al.
MOLECULAR THERAPY-ONCOLYTICS (2014)
Treatment Efficacy and Immune Stimulation by AdCD40L Gene Therapy of Spontaneous Canine Malignant Melanoma
Sara Westberg et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo et al.
NATURE MEDICINE (2013)
Safety Studies on Intravenous Administration of Oncolytic Recombinant Vesicular Stomatitis Virus in Purpose-Bred Beagle Dogs
Amy K. LeBlanc et al.
HUMAN GENE THERAPY CLINICAL DEVELOPMENT (2013)
Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients
Sandeep S. Patil et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Phase I Clinical Trial of a Genetically Modified Oncolytic Vaccinia Virus GL-ONC1 With Green Fluorescent Protein Imaging
A. Biondo et al.
EUROPEAN JOURNAL OF CANCER (2011)
A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma
Tae-Ho Hwang et al.
MOLECULAR THERAPY (2011)
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Caroline J. Breitbach et al.
NATURE (2011)
Dog models of naturally occurring cancer
Jennie L. Rowell et al.
TRENDS IN MOLECULAR MEDICINE (2011)
Long-lasting stability of Vaccinia virus strains in murine feces: implications for virus circulation and environmental maintenance
Jonatas S. Abrahao et al.
ARCHIVES OF VIROLOGY (2009)
Comparative expression pathway analysis of human and canine mammary tumors
Paolo Uva et al.
BMC GENOMICS (2009)
Eczema vaccinatum resulting from the transmission of vaccinia virus from a smallpox vaccinee: An investigation of potential fomites in the home environment
Edith Lederman et al.
VACCINE (2009)
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
David H. Kirn et al.
NATURE REVIEWS CANCER (2009)
Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma
Henrik von Euler et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Cancer incidence in pet dogs: Findings of the animal tumor registry of Genoa, Italy
D. F. Merlo et al.
JOURNAL OF VETERINARY INTERNAL MEDICINE (2008)
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
Byeong-Ho Park et al.
LANCET ONCOLOGY (2008)
Science and society - Translation of new cancer treatments from pet dogs to humans
Melissa Paoloni et al.
NATURE REVIEWS CANCER (2008)
Long-lasting stability of vaccinia virus (orthopoxvirus) in food and environmental samples
S. Essbauer et al.
ZOONOSES AND PUBLIC HEALTH (2007)
A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas
Farzan Siddiqui et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Administration of a conditionally replicative oncolytic canine adenovirus in normal dogs
Bruce F. Smith et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2006)
Fighting cancer with vaccinia virus: Teaching new tricks to an old dog
YQ Shen et al.
MOLECULAR THERAPY (2005)
Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2)
TM Jourdier et al.
GENE THERAPY (2003)
An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora
A Vermes et al.
CHEMOTHERAPY (2003)
Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions
A Vermes et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2000)
Naturally-occurring canine transitional cell carcinoma of the urinary bladder - A relevant model of human invasive bladder cancer
DW Knapp et al.
UROLOGIC ONCOLOGY (2000)
Spontaneously occurring tumors of companion animals as models for human cancer
DM Vail et al.
CANCER INVESTIGATION (2000)
Share Paper
